Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 671 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fallopian Tube Neoplasms Clear all
Terminated Phase 2 Interventional Results available

SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

NCT01200797
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
SJG-136, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
6
States / cities
Hartford, Connecticut • Tampa, Florida • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

NCT03508570
View directory record Official record
Conditions
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Peritoneal Carcinomatosis, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Malignant Female Reproductive System Neoplasm, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacokinetic Study
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer

NCT02275039
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
modified vaccinia virus ankara vaccine expressing p53, gemcitabine hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003944
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, paclitaxel, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jun 25, 2026, 8:21 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

NCT03641287
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Transitional Cell Carcinoma
Interventions
Exercise Counseling, Aerobic Exercise, Physiological Support, Quality-of-Life Assessment, Questionnaire Administration, Best Practice
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jun 25, 2026, 8:21 AM EDT
Active, not recruiting Phase 1 Interventional

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051
View directory record Official record
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

NCT05231122
View directory record Official record
Conditions
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Not applicable Interventional

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

NCT04537702
View directory record Official record
Conditions
Ovarian Cancer, Epithelial, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Streamlined Education, Traditional Education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Jun 25, 2026, 8:21 AM EDT
Suspended Phase 1 Interventional

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

NCT04711161
View directory record Official record
Conditions
Ovarian Tumors
Interventions
GRN-300, Paclitaxel
Drug
Lead sponsor
Green3Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jun 25, 2026, 8:21 AM EDT
Recruiting Early Phase 1 Interventional

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05080946
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Aspirin 325mg, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Tampa, Florida • Portland, Oregon • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025
View directory record Official record
Conditions
Solid Cancer
Interventions
R-DXd, Paclitaxel, Topotecan, PLD
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
43
States / cities
Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 32 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

NCT00268918
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
Interventions
Docetaxel, PTK787
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Jun 25, 2026, 8:21 AM EDT
Terminated Phase 1 Interventional

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

NCT03138408
View directory record Official record
Conditions
Cancer
Interventions
SC-004, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jun 25, 2026, 8:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ribociclib and Letrozole Treatment in Ovarian Cancer

NCT03673124
View directory record Official record
Conditions
Low Grade Serous Carcinoma
Interventions
Ribociclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
27
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 25, 2026, 8:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

NCT05271318
View directory record Official record
Conditions
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions
TILT-123, pembrolizumab, pegylated liposomal doxorubicin
Biological · Drug
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Not listed Phase 2 Interventional

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

NCT02188550
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
everolimus and letrozole
Drug
Lead sponsor
Sinai Hospital of Baltimore
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00317772
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

NCT00382811
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
Interventions
phenoxodiol, carboplatin, placebo
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
37
States / cities
Tuscon, Arizona • Glendale, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jun 25, 2026, 8:21 AM EDT
Not yet recruiting Phase 2 Interventional

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

NCT07495124
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

NCT01081262
View directory record Official record
Conditions
Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
Interventions
Bevacizumab, Capecitabine, Carboplatin, Laboratory Biomarker Analysis, Oxaliplatin, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
248
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Completed No phase listed Observational

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

NCT02315469
View directory record Official record
Conditions
Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Comprehensive Geriatric Assessment, Questionnaire Administration
Other
Lead sponsor
NRG Oncology
Other
Eligibility
70 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
392
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 282 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02111941
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 25, 2026, 8:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03586661
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Progressive Disease, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Copanlisib, Niraparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 8:21 AM EDT